Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Apremilast

Brand: Otezla®
NICE TA: 419
Indication: Moderate to severe plaque psoriasis (NICE TA419)
Disease category: Skin
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Apremilast is recommended as an option for treating chronic plaque psoriasis in adults whose disease has not responded to other systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and ultraviolet‑A light), or when these treatments are contraindicated or not tolerated, only if: • the disease is severe, as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 • treatment is stopped if the psoriasis has not responded adequately at 16 weeks; an adequate response is defined as: • a 75% reduction in the PASI score (PASI 75) from when treatment started or • a 50% reduction in the PASI score (PASI 50) and a 5‑point reduction in DLQI from start of treatment • the company provides apremilast with the discount agreed in the patient access scheme. When using the DLQI, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties, that could affect the responses to the DLQI and make any adjustments they consider appropriate.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red